Ondansetron Dosing and Frequency
Adults
For chemotherapy-induced nausea and vomiting (CINV), ondansetron 8 mg orally every 8–12 hours is the standard regimen, with a maximum daily dose of 24 mg (three 8 mg doses). 1, 2
Chemotherapy-Induced Nausea/Vomiting
- Moderately emetogenic chemotherapy: Ondansetron 16–24 mg orally as a single pretreatment dose, or 8 mg orally twice daily for 2 days after chemotherapy. 1, 2
- Highly emetogenic chemotherapy (Grade 3): Ondansetron 16 mg orally pretreatment, repeated twice daily for 2 days. 3
- Highly emetogenic chemotherapy (Grade 4 with cisplatin): Ondansetron 8 mg orally every 8–12 hours for 4–7 doses, combined with dexamethasone and/or a neurokinin-1 antagonist. 3
- Intravenous dosing: 8–12 mg IV (maximum 32 mg/day) before chemotherapy; for breakthrough nausea/vomiting, an 8 mg IV bolus followed by 1 mg/hour continuous infusion may be used in inpatients. 3, 1, 2
Radiation-Induced Nausea/Vomiting
- High-risk radiation (abdomen, pelvis): Ondansetron 8 mg orally 1–2 hours before each radiation fraction, repeated every 8 hours on radiation days. 4, 2
- Total body irradiation: Ondansetron 8 mg orally 1.5 hours before each fraction for 4 days. 2
- Maximum daily dose: 16 mg orally or 8 mg IV for breakthrough symptoms. 4
Postoperative Nausea/Vomiting (PONV)
- Prophylaxis: Ondansetron 16 mg orally as a single dose 1 hour before anesthesia induction. 2
- Intravenous alternative: 4 mg IV at induction or 30 minutes before skin closure. 5
- Oral regimen for extended prophylaxis: Ondansetron 8 mg orally three times daily for 24 hours postoperatively (not routinely recommended due to lack of additional benefit over single-dose regimens). 6
Children (≥4 Years)
For children ≥4 years with vomiting (e.g., acute gastroenteritis), ondansetron 8 mg orally as a single dose is appropriate for those weighing ≥40 kg; weight-based dosing of 0.15 mg/kg (maximum 8 mg) is used for lighter children. 7
Acute Gastroenteritis
- Single oral dose: 0.15 mg/kg (approximately 8 mg for children ≥40 kg) reduces vomiting episodes and the need for IV fluids by ~50%. 7
- Repeat dosing: If vomiting persists, the same dose may be repeated every 8 hours for up to 1–2 days, not exceeding 24 mg/day. 7
- Formulation: Orally disintegrating tablets (ODT) are preferred because they dissolve without water. 7
- Contraindications: Do not use in children with fever and severe abdominal pain (possible appendicitis), bloody diarrhea, or suspected surgical abdomen. 7
Chemotherapy-Induced Nausea/Vomiting (Pediatric)
- Initial IV dose: 0.15 mg/kg (range 0.04–0.87 mg/kg; total dose 2.16–12 mg) before chemotherapy, followed by oral ondansetron 4–24 mg daily for 3 days. 2
- Age-based oral dosing: Children <12 years receive 4 mg orally three times daily; children ≥12 years receive 8 mg orally three times daily. 2, 8
- Efficacy: Ondansetron 0.15 mg/kg IV or 0.1 mg/kg orally is significantly superior to metoclopramide, chlorpromazine, and placebo in preventing emesis. 8
Postoperative Nausea/Vomiting (Pediatric)
- Prophylaxis: Ondansetron 0.05–0.15 mg/kg IV (maximum 4 mg) administered intraoperatively. 9, 10, 8
- Optimal dose: 0.05 mg/kg (50 mcg/kg) IV is as effective as higher doses (100 mcg/kg) and superior to 10 mcg/kg or placebo. 9
- Timing: Administer during anesthesia or 30 minutes before skin closure. 10, 5
Maximum Daily Dose
The maximum daily dose of ondansetron is 24 mg for adults and children, regardless of indication. 1, 7, 2
- Oral: Three 8 mg doses (every 8 hours) = 24 mg/day. 1, 2
- Intravenous: 32 mg/day is the FDA-labeled maximum for IV administration, but doses >16 mg/day are associated with increased QT prolongation risk and are generally avoided. 1, 2
- Pediatric: Weight-based dosing (0.15 mg/kg every 8 hours) should not exceed 24 mg/day total. 7
Key Safety Considerations
- QT prolongation: Ondansetron prolongs the QT interval in a dose-dependent manner; avoid in patients with congenital long-QT syndrome or concurrent QT-prolonging drugs. 7, 2
- Diarrhea: Ondansetron increases stool frequency by 10–30% compared to placebo, particularly in gastroenteritis; this does not typically worsen dehydration. 7
- Serotonin syndrome: Risk is elevated when combined with other serotonergic agents (e.g., SSRIs, tramadol). 2
- Masking of ileus: Ondansetron may mask progressive ileus or gastric distension; avoid in suspected bowel obstruction. 2
- Hepatic impairment: Maximum daily dose is 8 mg in patients with severe hepatic dysfunction (Child-Pugh C). 2
Common Pitfalls
- Overuse in low-risk settings: Ondansetron is not indicated for minimal emetic risk chemotherapy or low-risk surgery; use simpler antiemetics (e.g., dexamethasone, prochlorperazine). 1, 4
- Exceeding maximum dose: Doses >24 mg/day orally or >16 mg/day IV increase adverse event risk without additional benefit. 1, 2
- Monotherapy for high-risk CINV: Ondansetron alone is insufficient for highly emetogenic chemotherapy; combine with dexamethasone and/or a neurokinin-1 antagonist (e.g., aprepitant). 1, 11
- Delayed administration in gastroenteritis: Ondansetron should be given first, then wait 15–30 minutes before offering oral rehydration solution to maximize fluid tolerance. 7